Synageva BioPharma Highlights Key Data Presentations at Upcoming Lysosomal Disease Network (LDN) World Symposium

LEXINGTON, Mass.--(BUSINESS WIRE)--Synageva BioPharma Corp. (“Synageva”) (NASDAQ:GEVA), a clinical stage biopharmaceutical company developing therapeutic products for rare disorders, today announced that three abstracts have been selected for oral presentation at the upcoming LDN WORLD Symposium being held February 8-10th in San Diego, California.
MORE ON THIS TOPIC